Search

Your search keyword '"Karam, Jose"' showing total 1,344 results
Start Over Author "Karam, Jose"
1,344 results on '"Karam, Jose"'

1. Vascular heterogeneity of tight junction Claudins guides organotropic metastasis

Author

Zhou, Xunian, LeBleu, Valerie S., Fletcher-Sananikone, Eliot, Kim, Jiha, Dai, Jianli, Li, Bingrui, Wu, Chia-Chin, Sugimoto, Hikaru, Miyake, Toru, Becker, Lisa M., Volpert, Olga V., Lawson, Erica, Espinosa Da Silva, Cristina, Patel, Sarah I., Kizu, Akane, Ehsanipour, Ehsan A., Sha, Di, Karam, Jose Antonio, McAndrews, Kathleen M., and Kalluri, Raghu

Published
2024
Full Text
View/download PDF

3. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805

Author

Karam, Jose A, Puligandla, Maneka, Flaherty, Keith T, Uzzo, Robert G, Matin, Surena F, Pins, Michael R, Wood, Christopher G, Kane, Christopher, Jewett, Michael AS, Kim, Eun, Dutcher, Janice P, DiPaola, Robert S, and Haas, Naomi B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Cancer, Clinical Research, Kidney Disease, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Disease-Free Survival, Humans, Kidney Neoplasms, Radiology, Sorafenib, Sunitinib, kidney cancer, adjuvant therapy, sarcomatoid, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectivesTo study the effects of adjuvant therapy in patients with sarcomatoid renal cell carcinoma (sRCC) enrolled in the randomised phase III clinical trial E2805.Patients and methodsThe original trial (E2805) was a randomised, double-blinded phase III clinical trial comparing outcomes in 1943 patients with RCC accrued between 2006 and 2010 and treated with up to 1 year of adjuvant placebo, sunitinib, or sorafenib. The present study analyses the cohort of patients with sRCC that participated in E2805.ResultsA total of 171 patients (8.8%) had sarcomatoid features. Of these, 52 patients received sunitinib, 58 received sorafenib, and 61 received placebo. Most patients were pT3-4 (71.1%, 63.7%, and 70.5%, respectively); 17.3%, 19.0%, and 27.9% had pathologically positive lymph nodes; and 59.6%, 62.1%, and 62.3% of the patients were University of California Los Angeles (UCLA) Integrated Staging System (UISS) very-high risk. In 49% of patients with subsequent development of metastatic disease, recurrence occurred in the lung, followed by 30% in the lymph nodes, and 13% in the liver. There was a high local recurrence rate in the renal bed (16%, 29%, and 18%, respectively). The 5-year disease-free survival (DFS) rates were 33.6%, 36.0%, and 27.8%, for sunitinib, sorafenib and placebo, respectively (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.45-1.20 for sunitinib vs placebo, and HR 0.82, 95% CI 0.53-1.28 for sorafenib vs placebo).ConclusionsAdjuvant therapy with sunitinib or sorafenib did not show an improvement in DFS or OS in patients with sRCC.

Published
2022

4. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections

Author

Falahkheirkhah, Kianoush, Guo, Tao, Hwang, Michael, Tamboli, Pheroze, Wood, Christopher G, Karam, Jose A, Sircar, Kanishka, and Bhargava, Rohit

Subjects
Electrical Engineering and Systems Science - Image and Video Processing, Computer Science - Computer Vision and Pattern Recognition, Computer Science - Machine Learning, Quantitative Biology - Quantitative Methods
Abstract

In clinical diagnostics and research involving histopathology, formalin fixed paraffin embedded (FFPE) tissue is almost universally favored for its superb image quality. However, tissue processing time (more than 24 hours) can slow decision-making. In contrast, fresh frozen (FF) processing (less than 1 hour) can yield rapid information but diagnostic accuracy is suboptimal due to lack of clearing, morphologic deformation and more frequent artifacts. Here, we bridge this gap using artificial intelligence. We synthesize FFPE-like images ,virtual FFPE, from FF images using a generative adversarial network (GAN) from 98 paired kidney samples derived from 40 patients. Five board-certified pathologists evaluated the results in a blinded test. Image quality of the virtual FFPE data was assessed to be high and showed a close resemblance to real FFPE images. Clinical assessments of disease on the virtual FFPE images showed a higher inter-observer agreement compared to FF images. The nearly instantaneously generated virtual FFPE images can not only reduce time to information but can facilitate more precise diagnosis from routine FF images without extraneous costs and effort., Comment: 24 pages, 6 figures, and 3 tables

Published
2021

5. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Author

Karam, Jose A., Msaouel, Pavlos, Haymaker, Cara L., Matin, Surena F., Campbell, Matthew T., Zurita, Amado J., Shah, Amishi Y., Wistuba, Ignacio I., Marmonti, Enrica, Duose, Dzifa Y., Parra, Edwin R., Soto, Luisa Maren Solis, Laberiano-Fernandez, Caddie, Lozano, Marisa, Abraham, Alice, Hallin, Max, Chin, Curtis D., Olson, Peter, Der-Torossian, Hirak, Yan, Xiaohong, Tannir, Nizar M., and Wood, Christopher G.

Published
2023
Full Text
View/download PDF

10. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy

Author

Hahn, Andrew W., Kotecha, Ritesh R., Viscuse, Paul V., Pieretti, Alberto C., Wiele, Andrew J., Jonasch, Eric, Lee, Chung-Han, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Y., Campbell, Matthew T., Sharma, Padmanee, Motzer, Robert J., Russo, Paul, Wood, Christopher G., Tannir, Nizar M., Voss, Martin H., Karam, Jose A., Hakimi, A. Ari, and Msaouel, Pavlos

Published
2023
Full Text
View/download PDF

13. Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma: A Tertiary Cancer Center Experience

Author

Abdelsalam, Mohamed E., primary, Mecci, Nabeel, additional, Awad, Ahmed, additional, Bassett, Roland L., additional, Odisio, Bruno C., additional, Habibollahi, Peiman, additional, Lu, Thomas, additional, Irwin, David, additional, Karam, Jose A., additional, Matin, Surena F., additional, and Ahrar, Kamran, additional

Published
2024
Full Text
View/download PDF

14. PD18-04 SURVIVAL IS DRAMATICALLY IMPROVED FOR MRCC PATIENTS WITH SARCOMATOID FEATURES WHO ARE TREATED WITH CYTOREDUCTIVE NEPHRECTOMY AND IMMUNE CHECKPOINT INHIBITORS REGARDLESS OF TREATMENT SEQUENCE

Author

Shapiro, Daniel D., primary, Karam, Jose A., additional, Master, Viraj A., additional, Spiess, Philippe E., additional, Peyton, Charles C., additional, Psutka, Sarah P., additional, Raman, Jay D., additional, Mercinelli, Chiara, additional, Nicaise, Edouard, additional, Robertson, Nicholas D., additional, Sirard, R. Barry, additional, Jani, Amber, additional, Necchi, Andrea, additional, Sexton, Wade J., additional, Manley, Brandon J., additional, Patil, Dattatraya, additional, Allen, Glenn O., additional, Matin, Surena F., additional, and Abel, Edwin J., additional

Published
2024
Full Text
View/download PDF

15. PD18-07 RISK FACTORS FOR PROGRESSION AND SURVIVAL IN MRCC PATIENTS WITH NO EVIDENCE OF DISEASE FOLLOWING CYTOREDUCTIVE NEPHRECTOMY WITH METASTASES DIRECTED THERAPY

Author

Shapiro, Daniel D., primary, Ghasemzadeh, Ali, additional, Peyton, Charles C., additional, Manley, Brandon J., additional, Sirard, R. Barry, additional, Robertson, Nicholas D., additional, Patel, Kartik R., additional, Nicaise, Edouard, additional, Jani, Amber, additional, Karam, Jose A., additional, Sexton, Wade J., additional, Patil, Dattatraya, additional, Allen, Glenn O., additional, Matin, Surena F., additional, Master, Viraj A., additional, Abel, Edwin J., additional, and Spiess, Philippe E., additional

Published
2024
Full Text
View/download PDF

16. PD18-06 VALIDATION OF THE SELECTION FOR CYTOREDUCTIVE NEPHRECTOMY (SCREEN) MODEL USING AN INDEPENDENT CONTEMPORARY MULTI-CENTER COHORT

Author

Abel, E. Jason, primary, Master, Viraj A., additional, Spiess, Philippe E., additional, Peyton, Charles C., additional, Psutka, Sarah P., additional, Raman, Jay D., additional, Mercinelli, Chiara, additional, Shapiro, Daniel D., additional, Nicaise, Edouard, additional, Robertson, Nicholas D., additional, Dolan, Brendan K., additional, Sirard, R. Barry, additional, Noonavath, Meghana, additional, Jani, Amber, additional, Necchi, Andrea, additional, Sexton, Wade J., additional, Manley, Brandon, additional, Patil, Dattatraya, additional, Allen, Glenn O., additional, Matin, Surena F., additional, and Karam, Jose A., additional

Published
2024
Full Text
View/download PDF

17. PD18-08 TUMOR SIZE REDUCTION (≥10%) RESULTING FROM PRE-SURGICAL SYSTEMIC THERAPY PREDICTS IMPROVED SURVIVAL FOLLOWING CYTOREDUCTIVE NEPHRECTOMY

Author

Shapiro, Daniel D., primary, Karam, Jose A., additional, Master, Viraj A., additional, Spiess, Philippe E., additional, Peyton, Charles C., additional, Dolan, Brendan, additional, Sirard, R. Barry, additional, Robertson, Nicholas D., additional, Patel, Kartik R., additional, Jani, Amber, additional, Patil, Dattatraya, additional, Nicaise, Edouard, additional, Manley, Brandon J., additional, Sexton, Wade J., additional, Allen, Glenn O., additional, Matin, Surena F., additional, and Abel, Edwin J., additional

Published
2024
Full Text
View/download PDF

19. Epidemiology of Renal Cell Carcinoma: 2022 Update

Author

Bukavina, Laura, Bensalah, Karim, Bray, Freddie, Carlo, Maria, Challacombe, Ben, Karam, Jose A., Kassouf, Wassim, Mitchell, Thomas, Montironi, Rodolfo, O'Brien, Tim, Panebianco, Valeria, Scelo, Ghislaine, Shuch, Brian, van Poppel, Hein, Blosser, Christopher D., and Psutka, Sarah P.

Published
2022
Full Text
View/download PDF

20. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Author

Pal, Sumanta Kumar, Uzzo, Robert, Karam, Jose Antonio, Master, Viraj A, Donskov, Frede, Suarez, Cristina, Albiges, Laurence, Rini, Brian, Tomita, Yoshihiko, Kann, Ariel Galapo, Procopio, Giuseppe, Massari, Francesco, Zibelman, Matthew, Antonyan, Igor, Huseni, Mahrukh, Basu, Debasmita, Ci, Bo, Leung, William, Khan, Omara, Dubey, Sarita, and Bex, Axel

Published
2022
Full Text
View/download PDF

21. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Tomczak, Piotr, Choueiri, Toni, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas R., Hajek, Jaroslav, Lin, Tzu-Ping, Symeonides, Stefan N., Lee, Jae Lyun, Sawrycki, Piotr, Haas, Naomi B., Gurney, Howard P., Mahave, Mauricio, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Chevreau, Christine, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Topart, Delphine, Oudard, Stephane, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Quinn, David I., Alva, Ajjai, Menezes, Juliana de Janoski, Silva, Adriano Goncalves e, Winquist, Eric W., Hamzaj, Alketa, Procopio, Giuseppe, Karaszewska, Boguslawa, Nowakowska-Zajdel, Ewa M., Alekseev, Boris Y., Gafanov, Rustem A., Izmailov, Adel, Semenov, Andrey, Afanasyev, Sergey G., Lipatov, Oleg N., Powles, Thomas B., Srinivas, Sandy, McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Chung, Jinsoo, Shkolnik, Michail I., Matveev, Vsevolod B., Gajate Borau, Pablo, McCune, Steven, Hutson, Thomas E., Dri, Alejandro, Sales, Silvio Correia, Yeung, Carrie, Alcala Castro, Carmen Marcela, Bostrom, Peter, Laguerre, Brigitte, Buttigliero, Consuelo, de Giorgi, Ugo, Fomin, Eugeniy A., Zakharia, Yousef, Hwang, Clara, Singer, Eric A., Yorio, Jeffrey T., Waterhouse, David, Kowalyszyn, Ruben Dario, Alfie, Margarita Sonia, Yanez Ruiz, Eduardo, Buchler, Tomas, Kankaanranta, Krista, Ferretti, Gianluigi, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Tamada, Satoshi, Kato, Haruaki, Kitamura, Hiroshi, Danielewicz, Iwona, Wojcik-Tomaszewska, Joanna, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Rojas-Uribe, Gustavo Adolfo, Gonzalez Fernandez, Manuel Enrique, Feyerabend, Susan, Pignata, Sandro, Numakura, Kazuyuki, Cybulska Stopa, Bozena, Zukov, Ruslan, Climent Duran, Miguel Angel, Maroto Rey, Pablo Jose, Montesa Pino, Alvaro, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Cobb, Patrick W., Hauke, Ralph, Anderson, Daniel M., Sarantopoulos, John, Gourdin, Theodore, Zhang, Tian, Jayram, Gautam, Fein, Luis Enrique, Harris, Carole, Beato, Patricia Medeiros Milhomem, Flores, Francisco, Estay, Angela, Rubiano, Juan Andres, Bedke, Jens, Hauser, Stefan, Neisius, Andreas, Busch, Jonas, Anai, Satoshi, Tsunemori, Hiroyuki, Sawka, Dariusz, Sikora-Kupis, Bozena, Arranz, Jose Angel, Delgado, Ignacio, Chen, Chung-Hsin, Gunderson, Elizabeth, Tykodi, Scott, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Kaen, Diego Lucas, Sade, Juan Pablo, Tatangelo, Marcelo Daniel, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Marceau, Daniele, Paradis, Jean-Benoit, Hanna, Nawar, Acevedo, Alejandro, Ibanez, Carolina, Villanueva, Luis, Galaz, Pedro Pablo, Durango, Isabel Cristina, Manneh, Ray, Kral, Zdenek, Holeckova, Petra, Hakkarainen, Heikki, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Tartas, Sophie, Goebell, Peter J., Grimm, Marc-Oliver, Hoefner, Thomas, Wirth, Manfred, Panic, Andrej, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Mizuno, Ryuichi, Uemura, Hirotsugu, Eto, Masatoshi, Tsujihata, Masao, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Hamberg, Paul, Marczewska-Skrodzka, Malgorzata, Szczylik, Cezary, Humphreys, Alison C., Jiang, Peter, Kumar, Birendra, Lu, Gary, Desai, Arpita, Karam, Jose Antonio, Keogh, George, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Mendez, Guillermo Ariel, Harris, Samuel J., Brown, Stephen J., Antonio Junior, Joao Neif, Costamilan, Rita de Cassia, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Lalani, Aly-Khan, Graham, Jeffrey, Levesque, Michael, Orlandi, Francisco, Kotasek, Rostislav, Deville, Jean L., Borchiellini, Delphine, Merseburger, Axel, Rink, Michael, Roos, Frederik, McDermott, Ray, Oyama, Masafumi, Yamamoto, Yoshiaki, Tomita, Yoshihiko, Miura, Yuji, Ioritani, Naomasa, Westgeest, Hans, Kubiatowski, Tomasz, Bal, Wieslaw, Girones Sarrio, Regina, Rowe, Julie, Prow, Debra M., Senecal, Francis, Hashemi-Sadraei, Neda, Cole, Scott W., Kendall, Stephan D., Richards, Donald A., Schnadig, Ian D., Gupta, Mukul, Powles, Thomas, Ferguson, Thomas, Symeonides, Stefan N, Gurney, Howard, Chang, Yen-Hwa, Haas, Naomi B, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Quinn, David I, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

26. INITIAL FINDINGS FROM THE MULTI-INSTITUTIONAL SARCOMATOID RENAL CELL CARCINOMA CONSORTIUM (SaRCC)

Author

Blum, Kyle A., primary, Mehr, Justin P., additional, Matin, Surena, additional, Karam, Jose A., additional, Pooli, Aydin, additional, Lebacle, Cedric, additional, Pantuck, Allan J., additional, Shuch, Brian, additional, Thompson, R. Houston, additional, Leibovich, Bradley, additional, Shah, Paras, additional, Hakimi, A. Ari, additional, and Russo, Paul, additional

Published
2024
Full Text
View/download PDF

32. Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination

Author

Ntowe, Koumani W., McAdoo, Sallie, Haas, Naomi B., Karam, Jose A., Lara, Primo N., Fashoyin-Aje, Ibilola, Saraiya, Biren P., Maskens, Deborah, Pickering, Lisa, Master, Viraj A., Zhang, Tian, and Kaye, Deborah R.

Abstract

Kidney cancer is amongst the deadliest genitourinary malignancies. Neoadjuvant systemic therapy has the potential to improve survival and overall outcomes in select patients. Enrolling patients in trials of neoadjuvant treatment for kidney cancer is challenging, which limits neoadjuvant treatment development. This study aims to develop a better understanding of the barriers patients face in kidney cancer clinical trial participation, with a particular focus on neoadjuvant trials for renal cell carcinoma. From 2022–2023, we recruited participants with a history of kidney cancer through a Qualtrics survey that was sent to the Kidney Cancer Association (KCA) and Kidney Cancer Cure (KCCure) mailing lists and social media pages. Patient responses on demographics, clinical information, and perspectives were evaluated. Ninety-four individuals completed the survey. Eighty-one percent of respondents reported not participating in clinical trials due to not being informed about potential applicable trials. Importantly, many (76%) respondents reported that prevention of cancer return was a highly important reason to participate in clinical trials. Most respondents reported a willingness to undergo a kidney biopsy (59%), and/or additional appointments (58%) and surgery delays. Increased patient awareness about clinical trials with the potential to delay cancer recurrence may increase patient participation in clinical trials. Clinical trial design, including additional appointments or interventions and/or minor surgery delays are not major barriers to trial participation.

Published
2024
Full Text
View/download PDF

33. Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups.

Author

Karam, Jose A., Bhattacharya, Rituparna, Ogbomo, Adesuwa, Gautam, Santosh, Yu, Rebekah, Sundaram, Murali, Imai, Kentaro, Chhabra, Jatin, and Haas, Naomi B.

Subjects
*RENAL cell carcinoma, *NEPHRECTOMY, *OVERALL survival, *PROGRESSION-free survival, *SURVIVAL rate
Abstract

Objectives: To examine real‐world characteristics, journey, and outcomes among patients with locoregional, nonmetastatic renal cell carcinoma (RCC). Methods: A retrospective analysis of medical records from the ConcertAI Oncology Dataset was performed on adults in the United States with newly diagnosed nonmetastatic RCC between January 2012–December 2017 who received surgical treatment, and were followed until August 2021. Patients were stratified based on the risk of recurrence after nephrectomy. Recurrence rate and survival outcomes were assessed. Results: The cohort (n = 439) had a median age of 64 years, 66.1% were male, and 76.5% had clear‐cell histology. The median follow‐up time from nephrectomy was 39.3 months overall, 41.0 months for intermediate‐high‐risk patients (n = 377; 85.9%) and 24.1 months for high‐risk patients (n = 62; 14.1%). For intermediate‐high‐ and high‐risk patients, respectively, 68.4% and 56.5% had ≥1 medical oncologist visit after nephrectomy. Of 260 patients with documentation of postoperative imaging assessments, 72% were ordered by medical oncologists, and the median time from initial nephrectomy to the first scan was 110 days (intermediate‐high‐risk) and 51 days (high‐risk). Provider‐documented recurrence occurred in 223 (50.8%) patients, of whom 41.7% had ≥1 medical oncologist visit before the recurrence. Three‐year disease‐free survival (DFS), and overall survival rates were 49.4% and 80.8% (all patients): 27.7% and 64.7% (high‐risk); and 52.9% and 83.3% (intermediate‐high‐risk). Conclusions: Our study reports low DFS after nephrectomy for patients with intermediate‐high‐ and high‐risk RCC. Subsequent approval and use of new and newly approved adjuvant therapeutic options could potentially delay or prevent recurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604–610

Author

Shapiro, Daniel D., primary, Karam, Jose A., additional, Master, Viraj A., additional, Sexton, Wade J., additional, Matin, Surena F., additional, Spiess, Philippe E., additional, and Abel, Edwin Jason, additional

Published
2023
Full Text
View/download PDF

38. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al’s Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.06.008

Author

Abel, E. Jason, primary, Master, Viraj A., additional, Spiess, Philippe E., additional, Raman, Jay D., additional, Shapiro, Daniel D., additional, Sexton, Wade J., additional, Zemp, Logan, additional, Patil, Dattatraya, additional, Lauer, Kate, additional, Allen, Glenn O., additional, Matin, Surena F., additional, and Karam, Jose A., additional

Published
2023
Full Text
View/download PDF

40. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

Author

Campbell, Matthew T., Matin, Surena F., Tam, Alda L., Sheth, Rahul A., Ahrar, Kamran, Tidwell, Rebecca S., Rao, Priya, Karam, Jose A., Wood, Christopher G., Tannir, Nizar M., Jonasch, Eric, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Y., Jindal, Sonali, Duan, Fei, Basu, Sreyashi, Chen, Hong, Espejo, Alexsandra B., Allison, James P., Yadav, Shalini S., and Sharma, Padmanee

Published
2021
Full Text
View/download PDF

41. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma

Author

Ruiz-Cordero, Roberto, Rao, Priya, Li, Lerong, Qi, Yuan, Atherton, Daniel, Peng, Bo, Singh, Rajesh R., Kim, Tae-Beom, Kawakami, Fumi, Routbort, Mark J., Alouch, Nail, Chow, Chi-Wan B., Tang, Ximing, Lu, Wei, Brimo, Fadi, Matin, Surena F., Wood, Christopher G., Tannir, Nizar M., Wistuba, Ignacio I., Chen, Ken, Wang, Jing, Medeiros, L.Jeffrey, Karam, Jose A., Tamboli, Pheroze, and Sircar, Kanishka

Published
2019
Full Text
View/download PDF

43. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent

Author

Merrill, Megan M, Wood, Christopher G, Tannir, Nizar M, Slack, Rebecca S, Babaian, Kara N, Jonasch, Eric, Pagliaro, Lance C, Compton, Zachary, Tamboli, Pheroze, Sircar, Kanishka, Pisters, Louis L, Matin, Surena F, and Karam, Jose A

Subjects
Cancer, Kidney Disease, Rare Diseases, Clinical Research, Patient Safety, Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, Cell Dedifferentiation, Disease Progression, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Nephrectomy, Treatment Outcome, Renal cell carcinoma, Sarcomatoid, Oncology and Carcinogenesis, Urology & Nephrology
Abstract

PurposeRenal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is an aggressive malignancy associated with a poor prognosis. Although existing literature focuses on patients presenting with metastatic disease, characteristics and outcomes for patients with localized disease are not well described. We aimed to evaluate postnephrectomy characteristics, outcomes, and predictors of survival in patients with sRCC who presented with clinically localized disease.Patients and methodsAn institutional review board-approved review from 1986 to 2011 identified 77 patients who presented with clinically localized disease, underwent nephrectomy, and had sRCC in their primary kidney tumor. Clinical and pathologic variables were captured for each patient. Overall survival (OS) and recurrence-free survival (RFS) were calculated for all patients and those who had no evidence of disease (NED) following nephrectomy, respectively. Comparisons were made with categorical groupings in proportional hazards regression models for univariable and multivariable analyses.ResultsOS for the entire cohort (n = 77) at 2 years was 50%. A total of 56 (77%) patients of the 73 who has NED following nephrectomy experienced a recurrence, with a median time to recurrence of 26.2 months. On multivariable analysis, tumor stage, pathologically positive lymph nodes, and year of nephrectomy were significant predictors of both OS and recurrence-free survival. Limitations include the retrospective nature of this study and relatively small sample size.ConclusionsLong-term survival for patients with sRCC, even in clinically localized disease, is poor. Aggressive surveillance of those who have NED following nephrectomy is essential, and further prospective studies evaluating the benefit of adjuvant systemic therapies in this cohort are warranted.

Published
2015

44. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study

Author

Aydin, Ahmet M., Singla, Nirmish, Panwar, Vandana, Woldu, Solomon L., Freifeld, Yuval, Wood, Christopher G., Karam, Jose A., Weizer, Alon Z., Raman, Jay D., Remzi, Mesut, Rioux-Leclercq, Nathalie, Haitel, Andrea, Roscigno, Marco, Bolenz, Christian, Bensalah, Karim, Westerman, Mary E., Sagalowsky, Arthur I., Shariat, Shahrokh F., Lotan, Yair, Bagrodia, Aditya, Kapur, Payal, Margulis, Vitaly, and Krabbe, Laura-Maria

Published
2019
Full Text
View/download PDF

47. Partial Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma

Author

Babaian, Kara N, Merrill, Megan M, Matin, Surena, Tamboli, Pheroze, Tannir, Nizar M, Jonasch, Eric, Wood, Christopher G, and Karam, Jose A

Subjects
Cancer, Prevention, Kidney Disease, 6.4 Surgery, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Nephrectomy, Retrospective Studies, carcinoma, diagnosis, kidney, neoplasm metastasis, nephrectomy, renal cell
Abstract

PurposeCytoreductive nephrectomy remains the standard of care for appropriately selected patients with metastatic renal cell carcinoma. Although the role of partial nephrectomy is well accepted in patients with localized disease, limited data are available on partial nephrectomy in the metastatic setting. We identified the indications for and outcomes of partial nephrectomy in the setting of metastatic renal cell carcinoma with particular attention to partial nephrectomy subgroups.Materials and methodsWe analyzed data on a consecutive cohort of 33 patients with metastatic renal cell carcinoma who underwent partial nephrectomy at a single institution between 1996 and 2011. Nonparametric statistics were used to compare partial nephrectomy subgroups. Overall survival was estimated using the Kaplan-Meier method and survival functions were compared using the log rank test.ResultsAt presentation 8 patients had bilateral synchronous renal masses, 20 had a metachronous contralateral renal mass and 5 had a unilateral renal mass. A total of 22 patients (67%) died of disease a median of 27 months postoperatively. Patients who underwent partial nephrectomy for a metachronous contralateral renal mass and a renal mass 4 cm or less had the best overall survival (61 and 42 months, respectively). Median overall survival in patients with vs without metastatic disease at original diagnosis was 27 vs 63 months (p = 0.003).ConclusionsOur findings suggest that metastasis at the original diagnosis and the timing of presentation of the partial nephrectomy index lesion have an important role in survival. These factors should be considered when determining which patients would benefit from partial nephrectomy in the setting of metastatic renal cell carcinoma.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results